Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

25/08/2016 - 2 minutes

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun!

Galapagos_septemer_stocks_nasdaq_filgotinib_abbvie_gilead_dealGalapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not the first time Galapagos has been hung out to dry by a partner, but this time, Gilead picked up the slack. Despite this boost, AbbVie remains in the lead with its competitor, ABT-494; Eli Lilly and Pfizer also have horses in the race, baricitinib and Xeljanz respectively.

Galapagos and Gilead are now enrolling patients in its first of three Phase III trials for filgotinib, a JAK1 inhibitor to fight rheumatoid arthritis. AbbVie started enrolling patients to receive ABT-494 in January, giving it an 8-month head start. Its lead could increase even further, as AbbVie’s trials are shorter and smaller than those for filgotinib.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member